A Genetic Polymorphism in CTLA-4 Is Associated with Overall Survival in Sunitinib-Treated Patients with Clear Cell Metastatic Renal Cell Carcinoma

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Clinical Cancer Research

• Publication date

  2018-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-17-2815PMID 29490989
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.

  2017cited by this paper
• The prognostic value of cytotoxic T-lymphocyte antigen 4 in cancers: a systematic review and meta-analysis

  2017cited by this paper
• Functional polymorphisms in PD-L1 gene are associated with the prognosis of patients with early stage non-small cell lung cancer.

  2017cited by this paper
• Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

  2017cited by this paper
• Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma

  2017cited by this paper
• Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer

  2016cited by this paper
• Meta-analysis on the association of VEGFR1 genetic variants with sunitinib outcome in metastatic renal cell carcinoma patients

  2016cited by this paper
• Higher preoperative serum levels of PD‐L1 and B7‐H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF‐targeted therapy and unfavorable prognosis of renal cell carcinoma

  2016cited by this paper
• Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer

  2016cited by this paper
• OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs

  2016influential reference
• Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis

  2016cited by this paper
• PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis

  2015cited by this paper
• International variations and trends in renal cell carcinoma incidence and mortality.

  2015cited by this paper
• Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

  2015cited by this paper
• Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial

  2014cited by this paper
• 1052PDNIVOLUMAB (N) (ANTI-PD-1; BMS-936558, ONO-4538) IN COMBINATION WITH SUNITINIB (S) OR PAZOPANIB (P) IN PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC).

  2014cited by this paper
• CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer

  2013cited by this paper
• The Genotype-Tissue Expression (GTEx) project

  2013cited by this paper
• COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA

  2013cited by this paper
• CTLA-4 +49A>G Polymorphism Is Associated with Advanced Non-Small Cell Lung Cancer Prognosis

  2011cited by this paper
• Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma

  2011cited by this paper
• MICE: Multivariate Imputation by Chained Equations in R

  2011cited by this paper
• New insights of CTLA-4 into its biological function in breast cancer.

  2010cited by this paper
• Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

  2009cited by this paper
• Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade

  2008cited by this paper
• Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer.

  2008cited by this paper
• Oxidative Stress Regulates Expression of VEGFR1 in Myeloid Cells: Link to Tumor-Induced Immune Suppression in Renal Cell Carcinoma1

  2008cited by this paper
• A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism

  2007cited by this paper
• Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up.

  2006cited by this paper
• Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation.

  2006cited by this paper
• Efficiency and power in genetic association studies

  2005cited by this paper
• A Common Autoimmunity Predisposing Signal Peptide Variant of the Cytotoxic T-lymphocyte Antigen 4 Results in Inefficient Glycosylation of the Susceptibility Allele*

  2002cited by this paper
• CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms

  2001cited by this paper
• The CTLA-4 gene region of chromosome 2q33 is linked to, and associated with, type 1 diabetes. Belgian Diabetes Registry.

  1996cited by this paper
• No Adjustments Are Needed for Multiple Comparisons

  1990cited by this paper

• Insights into the mechanisms of drug resistance in renal cell carcinoma: from multi-omics perspective.

  2026cites this paper
• CTLA4 genetic variants influence immune regulation and susceptibility of HPV associated cervical cancer

  2025cites this paper
• Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study

  2025cites this paper
• Malaria-derived hemozoin skews dendritic cell responses to bacterial infections by reducing interferon gene-transcription by SWI/SNF-NuRD

  2025cites this paper
• Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma

  2023cites this paper
• PD1.5 variant on PDCD1 gene, regulator of T lymphocyte activity, influences non-muscle-invasive bladder cancer risk.

  2022cites this paper
• Identification of a Novel Glycolysis-Related Gene Signature Correlates With the Prognosis and Therapeutic Responses in Patients With Clear Cell Renal Cell Carcinoma

  2021cites this paper
• PD-L1 Expression and Treatment Implications in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review

  2021influential citation
• A prisma-compliant meta-analysis

  2020cites this paper
• Genetic variants in a long noncoding RNA related to Sunitinib Resistance predict risk and survival of patients with renal cell carcinoma

  2019cites this paper
• Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy

  2019cites this paper
• Germinal immunogenetics as a predictive factor for immunotherapy.

  2019cites this paper
• Expression of PD-1 and CTLA-4 Are Negative Prognostic Markers in Renal Cell Carcinoma

  2019cites this paper
• HEREDITARY ENDOCRINE CANCER GROUP

  2017cites this paper